Lundbeck buys Alder in $2 billion migraine treatment move
Share:
COPENHAGEN (Reuters) - Denmark's Lundbeck will buy U.S. drug developer Alder BioPharmaceuticals in a deal valued at almost $2 billion.Lundbeck, specialising in brain diseases such as Alzheimer's and depression, has sought acquisitions and partnerships as it faces patent expirations and competition from generic drugs.Alder, whose board has unanimously approved the takeover, develops preventative treatments of migraine in adults and has submitted a Biologics License Application for its..